Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



CAPScall of the Week: Complete Genomics

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S. districts and its congressional representative. While I am no Stephen Colbert, I am brutally inquisitive when it comes to the 5,000-plus listed companies on the U.S. stock exchanges.

That's why this week and every week from here on out, I'll make it a tradition to examine one seldom-followed company within the Motley Fool CAPS database and make a CAPScall of outperform or underperform on that company.

For this week's round of what I like to call "Better Know a Stock," I'd like to take a closer look at Complete Genomics (Nasdaq: GNOM  ) .

What Complete Genomics does
Complete Genomics is a life sciences company developing DNA sequencing technology to quickly and cost-effectively analyze DNA data. The main buzz surrounding Complete Genomics is its announcement that it has developed new genome sequencing technology, known as Long Fragment Read, which is significantly more accurate than what's currently available on the market and requires less DNA for analysis. Genome sequencers are vital to researchers as they allow for quicker turnaround times in studies. Also, as genome sequencing costs fall, research studies become cheaper and more feasible to run.

In Complete Genomics' latest quarter, the company noted revenue of $3.9 million, down from $6.8 million in the previous year, while expenses ballooned due to DNA sequencing technology development.

Whom it competes against
As you can imagine, competition among life sciences companies is fierce. Illumina (Nasdaq: ILMN  ) is currently suing Complete Genomics for allegedly infringing on a single method of sequencing a polynucleotide template. This lawsuit was filed at the same time that Roche was attempting its hostile takeover of Illumina (which Illumina successfully fended off).

Also, Life Technologies' (Nasdaq: LIFE  ) new Benchtop Ion Proton Sequencer is capable of sequencing the human genome in just one day, for the tidy sum of just $1,000. This significant reduction in time and cost could be a game-changer that puts its technology out of the reach of its competitors. Big pharmaceutical companies are starting to take notice of Life's superior technology, such as when GlaxoSmithKline (NYSE: GSK  ) and Life Technologies partnered up in 2011 to develop a companion test for a cancer drug. But did I mention the lawsuits? Pacific Biosciences (Nasdaq: PACB  ) won a lawsuit last year against Life Technologies regarding the technology surrounding single-molecule sequencing.

In short, Complete Genomics competes as much against its competitors' lawyers as it does against their innovation.

The call
After reviewing Complete Genomics' prospects, I've decided to make a CAPScall of underperform on the company.

In spite of Complete Genomics' new LFR technology, I'm concerned the company is quickly running out of cash. Complete ended its latest quarter with just $63.1 million in cash ($40.2 million net cash), and an increasing cash burn rate ($36 million in 2008, $54 million in 2009, $71 million in 2010, and $78 million over the last 12 months) that shows no sign of letting up. That leaves Complete with few options other than to sell itself on the cheap, sell the rights to its new technology to raise cash, or dilute the daylights out of its current shareholders. There's also no guarantee, even if it does issue a dilutive share offering, that its technology will be widely accepted or effectively be able to compete against Illumina and Life Technologies, which have much larger partners and deeper pockets. With the company cutting 55 of its 255 jobs and delaying its expansion, I think that's all the incentive I need to rate this stock as underperform.

You can follow this selection, as well as all previous CAPScalls I've made, by clicking here to be immediately whisked away to my CAPS portfolio.

Although Complete Genomics doesn't exactly fit the bill of a company you can retire on, our Motley Fool think tank of analysts does have three companies in mind. Click here to get our latest special free report and find out which three stocks could have you sleeping better at night.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Motley Fool newsletter services have recommended buying shares of Illumina and Pacific Biosciences of California. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that has transparency written in its DNA.

Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 20, 2012, at 1:21 PM, garifolle wrote:

    Unfortunally I must agree with you.

    I liked this company that rewarded me nicely short after it's IPO, I have never stopped following it.

    I missed the recent 44% rally, but I could not understand why people got so excited.

    I should say investors or traders, because I guess that for science and technological knowledge, it was a real event.

    The only thing that one could hope would be that they would be taken over by a solid firm that could afford the huge costs.

    But in your paragraphe:

    Whom it competes against, you only mention the publicly traded companies.

    There are so many non traded companies or even only research groups that could find breaking technologies that could be bought probably cheaper, that even the probabilty of a merger is very slim.

  • Report this Comment On July 20, 2012, at 7:02 PM, gnomfan wrote:

    Horrible call. Cash/Burn can easily be rectified by cutting costs. Remember most of their cash has been going to R&D which is at or near completion max 2yrs. They are building more powerful sequencing machines that may change modern medicine as we know it and bring the cost per sequence down while determining fantastic results. Diluting shareholders is not the only way to raise cash, they DO have an inventory backlog that they can realize revenue for, issue a corporate bond, or the old fashion way - take out a loan. They just need to buy time and then will start to sequence 10-20K per quarter. Do the math.....

  • Report this Comment On July 21, 2012, at 4:25 PM, hacker44240 wrote:

    I hate reading articles on Motley Gruel for just this reason. Not only does the author not know a single thing about science or technology, but they are totally clueless about the company and especially the company's competitors. The only direct competitors that GNOM has are BGI in China, and the so-called Illumina Genome network (they will put you in contact with these 3 unknown academic centers to help you get your sequencing done). Go look on ILMN financial statements and try to find the line items for contract sequencing service. It does not exist. GNOM's technology is far better than ILMN, but they are in 2 totally different businesses. ILMN sells boxes, GNOM does contract sequencing. GNOM's main issues right now are they are too early. Clinical application of sequencing is just now starting to mature. So cash flow is the real issue.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1950159, ~/Articles/ArticleHandler.aspx, 10/28/2016 10:48:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,222.66 52.98 0.29%
S&P 500 2,138.80 5.76 0.27%
NASD 5,226.19 10.22 0.20%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
GNOM.DL $0.00 Down +0.00 +0.00%
Complete Genomics CAPS Rating: **
GSK $40.27 Down -0.15 -0.37%
GlaxoSmithKline CAPS Rating: ***
ILMN $140.24 Up +0.95 +0.68%
Illumina CAPS Rating: *****
LIFE.DL $0.00 Down +0.00 +0.00%
Life Technologies… CAPS Rating: ***
PACB $8.52 Up +0.02 +0.24%
Pacific Bioscience… CAPS Rating: ***